Literature DB >> 28939460

Pharmacotherapy Use in Older Patients With Heart Failure and Reduced Ejection Fraction After a Skilled Nursing Facility Stay.

Lin Li1, Bill M Jesdale2, Anne Hume3, Giovanni Gambassi4, Robert J Goldberg2, Kate L Lapane2.   

Abstract

BACKGROUND: Little is known about guideline-directed pharmacotherapy use in patients with heart failure and reduced ejection fraction (HFrEF) discharged to skilled nursing facilities (SNFs). This study aimed to describe the use of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blocker (ARBs) and evidence-based β-blockers (EBBBs) among older patients with HFrEF within 90 days after the SNF admission and to identify factors associated with receipt of these medications. METHODS AND
RESULTS: With the use of Minimum Data Set 3.0 cross-linked with Medicare data (2011-2012), we studied 35,792 Americans aged ≥65 years with HFrEF admitted to 10,333 SNFs. The median age was 82 years, 59% were women, 81% had at least moderate physical limitations, and 39% had moderate/severe cognitive impairment. Fifty-six percent received an ACEI/ARB and 53% an EBBB; one-fourth received neither. In a multivariable log-binomial model, advanced age, severe physical limitations, and greater number of comorbid conditions not associated with heart failure were inversely associated with ACEI/ARB and EBBB receipt.
CONCLUSIONS: Use of standard pharmacotherapy among patients with HFrEF after an SNF stay is higher than previously reported. In the absence of evidence demonstrating the effectiveness of ACEIs/ARBs and EBBBs in this population, whether or not improvements in prescribing are warranted remains unknown.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure with reduced ejection fraction; angiotensin-converting enzyme inhibitors; skilled nursing facility; β-blockers

Mesh:

Substances:

Year:  2017        PMID: 28939460      PMCID: PMC5711557          DOI: 10.1016/j.cardfail.2017.09.007

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  36 in total

1.  Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials.

Authors:  Brian R Dulin; Steven J Haas; William T Abraham; Henry Krum
Journal:  Am J Cardiol       Date:  2005-04-01       Impact factor: 2.778

2.  The impact of Medicare Part D on prescription drug use by the elderly.

Authors:  Frank R Lichtenberg; Shawn X Sun
Journal:  Health Aff (Millwood)       Date:  2007 Nov-Dec       Impact factor: 6.301

3.  Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients.

Authors:  Qian Li; Robert J Glynn; Nancy A Dreyer; Jun Liu; Helen Mogun; Soko Setoguchi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-05-14       Impact factor: 2.890

4.  Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes.

Authors:  John A Dodson; Tuyet-Trinh N Truong; Virginia R Towle; Gerard Kerins; Sarwat I Chaudhry
Journal:  Am J Med       Date:  2013-02       Impact factor: 4.965

5.  Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old.

Authors:  Maarten Wauters; Monique Elseviers; Bert Vaes; Jan Degryse; Olivia Dalleur; Robert Vander Stichele; Thierry Christiaens; Majda Azermai
Journal:  Br J Clin Pharmacol       Date:  2016-08-03       Impact factor: 4.335

6.  Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.

Authors:  Luis Sargento; Andre Vicente Simões; Susana Longo; Nuno Lousada; Roberto Palma Dos Reis
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

7.  Comparison of Length of Stay, 30-Day Mortality, and 30-Day Readmission Rates in Medicare Patients With Heart Failure and With Reduced Versus Preserved Ejection Fraction.

Authors:  Matthew Shane Loop; Melissa K Van Dyke; Ligong Chen; Todd M Brown; Raegan W Durant; Monika M Safford; Emily B Levitan
Journal:  Am J Cardiol       Date:  2016-04-21       Impact factor: 2.778

8.  Sensitivity and specificity of the Minimum Data Set 3.0 discharge data relative to Medicare claims.

Authors:  Momotazur Rahman; Denise Tyler; Joseph Kofi Acquah; Julie Lima; Vincent Mor
Journal:  J Am Med Dir Assoc       Date:  2014-08-30       Impact factor: 4.669

9.  Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications.

Authors:  Ali Ahmed; Catarina I Kiefe; Richard M Allman; Richard V Sims; James F DeLong
Journal:  J Am Geriatr Soc       Date:  2002-10       Impact factor: 5.562

10.  Trends in the medical management of patients with heart failure.

Authors:  Samuel W Joffe; Matthew Dewolf; Jeffrey Shih; David D McManus; Frederick A Spencer; Darleen Lessard; Joel M Gore; Robert J Goldberg
Journal:  J Clin Med Res       Date:  2013-04-23
View more
  2 in total

1.  Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.

Authors:  Matthew Shane Loop; Melissa K van Dyke; Ligong Chen; Monika M Safford; Meredith L Kilgore; Todd M Brown; Raegan W Durant; Emily B Levitan
Journal:  J Card Fail       Date:  2018-10-16       Impact factor: 5.712

2.  Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE).

Authors:  Reem K Jan; Alawi Alsheikh-Ali; Arif Al Mulla; Kadhim Sulaiman; Prashanth Panduranga; Wael Al-Mahmeed; Nooshin Bazargani; Jassim Al-Suwaidi; Mohammed Al-Jarallah; Ahmed Al-Motarreb; Amar Salam; Ibrahim Al-Zakwani
Journal:  Medicine (Baltimore)       Date:  2022-06-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.